A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion

Trial Profile

A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2012

At a glance

  • Drugs Lorvotuzumab mertansine (Primary)
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 11 Oct 2010 Encouraging results were presented at ESMO 2010, as reported in an ImmunoGen Inc., media release.
    • 01 Aug 2009 Results are being presented at the 13th World Conference on Lung Cancer, according to an Immunogen media release.
    • 08 Jan 2009 Actual patient number reported as 32 by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top